Research group - Erik Eliasson
Our research aims to better understand and predict the individual patient response to drug treatment. There is considerable variability between individuals that may include therapeutic failures or severe adverse drug reactions at standard dosing.
To overcome this clinical uncertainty, we wish to develop mechanism-based laboratory markers with predictive power and offer monitoring possibilities during treatment to individualize dose regimens. This represents a classical Precision Medicine approach and more specifically the present scope is (1) to individualize the use of critical antibiotics against life-threatening infections such as sepsis or endocarditis, by introduction of novel pharmacokinetic-pharmacodynamic modelling tools that helps to define optimal dose in the individual case (2) to explore genetic differences in the highly polymorphic metabolism of tamoxifen and capecitabine in breast cancer treatment in order to secure effective treatment without severe adverse drug reactions.
Senior collaborators (professors/associate professors) include Jonatan Lindh, Sara Margolin, Per Hall, Kamila Czene, Jonas Bergh, Volker Lauschke, Magnus Ingelman-Sundberg, Christian Giske, Johan Petersson (Stockholm), Elisabet Nielsen, Mia Wadelius (Uppsala), and Espen Molden (Oslo).
Research group leader Erik Eliasson
Erik Eliasson
Professor/senior physicianGroup members
Yitian Zhou
Affiliated to researchResearch techniques
Bioanalysis mainly LC-MS/MS, microdialysis, drug metabolism in vitro/in vivo, pharmacokinetic analysis and popPK modelling, genotyping, NGS, bioinformatics, prediction of functional impact and phenotyping of genetic variants, GCP, register-based studies on drug dispensation, treatment efficacy and adverse drug reactions
External funding
Vinnova, ALF, CIMED.
Selected publications
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E
Br J Clin Pharmacol 2021 03;87(3):1243-1252
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, Hammarström M, Margolin S, Thorén L, Wengström Y, Borgquist S, Hall P, Czene K
Ann Oncol 2021 10;32(10):1286-1293
Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.
Petersson J, Giske CG, Eliasson E
Antimicrob Agents Chemother 2021 03;65(4):
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J, Mannheimer B, Malmström RE, Eliasson E, Lindh JD
Eur J Clin Pharmacol 2021 Mar;77(3):409-419
[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure].
Eliasson E, Wadelius M
Lakartidningen 2021 05;118():